IBIosif Beintaris

Iosif Beintaris

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Iosif Beintaris has a total of 89 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Periappendiceal polyps: a single centre case series and review of literature

    by Mahmoud Mohamed, Iosif Beintaris, Clare Westwood, John Jacob, Abimbola Aduroja, Matt Rutter

    Periappendiceal polyps present a unique challenge to the endoscopist, as they are often difficult to detect and access in their entirety, frequently extending deep into the appendix. High rates of incomplete resection and procedural risks add to these challenges. Their clinical significance, optimal management strategies and long-term outcomes require further attention. Current management options include surgery, endoscopic mucosal resection (EMR) and newer techniques such as endoscopic full-thickness resection, underwater EMR, endoscopic submucosal dissection and combined endoscopic–laparoscopic resection. This study aims to describe the clinical presentation, management and outcomes of a series of patients with periappendiceal polyps treated in our NHS Trust, with particular emphasis on the multidisciplinary team (MDT) decision-making process and practical considerations for frontline endoscopists. We conducted a retrospective observational study involving 32 patients diagnosed with periappendiceal polyps. Data was collected on demographics, clinical indications for colonoscopy, treatment modalities, histological findings, complications and follow-up outcomes. All cases were discussed in an MDT meeting involving endoscopists, surgeons and radiologists. Polyps were assessed using narrow band imaging (NBI) during colonoscopy to enhance vascular and surface features and assist in the real-time differentiation of hyperplastic polyps, adenomas and sessile serrated lesions (SSLs). NBI International Colorectal Endoscopic classification was routinely applied in line with UK practice. Descriptive statistics were employed for data analysis. The most common indication for colonoscopy was a positive faecal immunochemical test in the National Health Service Bowel Cancer Screening Programme (53.1%). The mean polyp size was 14.1 mm (SD=10.82 mm), with 96.9% of patients having a single periappendiceal polyp. All cases were discussed in an MDT meeting. Endoscopic management was performed in 43.75% of cases, with 12 polyps treated by EMR and 2 by cold snare polypectomy. Surgical management was decided for a few sizeable polyps or those with increased suspicion of malignancy, resulting in appendicectomy for five patients and right hemicolectomy for two. 11 patients were managed conservatively due to associated comorbidities following MDT assessment of fitness for intervention. Histopathological analysis revealed a diverse range of lesions, including 12 SSLs without dysplasia, 6 low-grade tubulovillous adenomas (TVA), 6 low-grade tubular adenomas, 2 hyperplastic polyps and 1 high-grade TVA. Notably, two surgical cases revealed only lymphoid aggregates, highlighting the importance of preresection biopsy to avoid unnecessary surgical intervention, in cases where the endoscopist is not convinced they are dealing with a ‘true’ polyp. Follow-up data was available for 11 patients, with a median site check follow-up of 15 months (range 3 months to 3 years), without signs of endoscopic recurrence in any of these cases. One possible complication reported was appendicitis, which occurred 3 months postpolypectomy. Periappendiceal polyps exhibit histopathological diversity, with SSLs being the most common finding in our series. Although resection can be technically challenging, with appropriate expertise and a collaborative multidisciplinary approach, most lesions can be managed effectively through endoscopic techniques. The MDT approach is crucial for optimising patient selection, avoiding unnecessary interventions and ensuring appropriate follow-up. This case series adds to the currently limited literature on periappendiceal polyps and provides practical insights for their management in routine clinical practice.

  • Effectiveness and safety of a haemostatic gel in the treatment of intraprocedural bleeding and prevention of delayed bleeding after advanced endoscopic resection of large and complex gastrointestinal neoplasia: a multicentre prospective observational PuraStat study

    by Hein Myat Thu Htet, Sharmila Subramaniam, Adolfo Parra-Blanco, Brian Saunders, Noriko Suzuki, Amyn Haji, Bu’hUssain Hayee, Yeng Ang, Massimiliano di Pietro, Marietta Iacucci, et al.

    Objective: PuraStat is a topical haemostatic agent used for treatment and prevention of bleeding. Our aim was to evaluate the efficacy and safety of using PuraStat during advanced endoscopic resection procedures in a multicentre prospective setting. Design/methods: This is a multicentre prospective evaluation on efficacy and safety of PuraStat when used in the treatment of intraprocedural bleeding and prevention of delayed bleeding during the study period from 2019 to 2021. High-risk tissue resections (HRTR) with endoscopic mucosal resection (EMR) or endoscopic submucosal dissection (ESD) for large and complex lesions from the oesophagus, stomach, duodenum and colon were included. Data on the type of bleed, haemostatic measures used, and efficacy and safety of PuraStat were prospectively collected. A descriptive analysis was performed and expressed as proportions. Results: PuraStat was used in a total of 448 patients with HRTR. PuraStat was used for treatment of intraprocedural bleeding in 105 patients. Overall haemostatic efficacy in this group was 91.43%. All 448 patients had prophylactic application of PuraStat on the resection base to prevent delayed bleeding. The observed overall delayed bleeding rate for the entire cohort was 1.34%. On subgroup analysis, we found that this was highest in the duodenum (8.69%) followed by 1.80% in the right colon (EMR and ESD). There were no delayed bleeds in the oesophagus, stomach and left colon. Conclusions: Our data demonstrates that PuraStat is safe and appears to be effective in the treatment of intraprocedural bleeding and prevention of delayed bleeding after high-risk endoscopic resections. Trial registration number: NCT03983707 .

  • The impact of a multidisciplinary team approach on the management of patients diagnosed with complex colorectal polyps

    by Clare Westwood, David Beaton, Iosif Beintaris, John Jacob, Kevin Etherson, Ravi Ranjan, Matthew D. Rutter

    Aim: Large nonpedunculated colorectal polyps (LNPCPs) have a greater than average risk of malignancy, incomplete resection/recurrence and complications associated with treatment. Appropriate management of these lesions is crucial to prevent cancer and reduce harm. The British Society of Gastroenterologists (BSG) and the Association of Coloproctologists of Great Britain and Ireland (ACPGBI) published guidelines for the management of LNPCPs in 2015. The aim of this work was to evaluate the case mix and outcomes from a single centre's multidisciplinary approach to managing such lesions against the key performance indicators (KPIs) set within these national guidelines.Method: Cohort study from a single centre over a 2‐year period, January 2020 to December 2022.Results: After exclusions, a total of 229 cases were discussed. Most complex polyps were treated endoscopically, with conservative management recommended in 22 cases where patients had significant comorbidities and were unlikely to benefit from therapy. The overall surgical intervention rate (including transanal endoscopic microsurgery/per anal excision) was 14%. Of the cases treated endoscopically, there was residual polyp detected in 3.9% at 12‐months’ follow‐up. Complications were rare. There was a single case of perforation following endoscopic submucosal dissection and no significant postprocedure bleeds. There were no perforations following endoscopic mucosal resection, although postpolypectomy bleeding requiring admission occurred in 4%. Sixty‐eight per cent of patients were treated within 56 days of multidisciplinary team (MDT) discussion, despite the timeframe being within a period of huge disruption due to the global COVID pandemic. KPI standards published by the BSG were therefore met.Conclusion: MDT management of complex polyps (LNPCPs) is effective and meets the standards set by national guidance. Patient outcomes following treatment for complex polypectomy are improved when the most appropriate procedure is performed by the most appropriate operator. Discussion at a complex polyp MDT can facilitate this approach.


  • Open Access

    Postcolonoscopy Diverticulitis

    by Mahmoud E. Essam, Iosif Beintaris, Matthew D. Rutter

    Assessment (DICA) score of 2, indicating extensive diverticulosis without inflammation. Conservative management with antibiotics led to recovery. Remarkably, she experienced a recurrent episode. Case 2 was a 74-year-old woman who had 2 colonoscopies, revealing pancolonic diverticulosis (DICA score: 2) without inflammation. After the second procedure, she developed severe sigmoid diverticulitis, managed conservatively with antibiotics. Discussion highlights PCD's rarity (prevalence: 0.04%–0.08%) and unclear pathogenesis. Both cases had DICA scores ≥2, suggesting a potential risk factor. Clinicians should recognize PCD, as it can mimic more common postcolonoscopy complications. Early recognition and management are vital....

  • Colonoscopic cancer detection rate: a new performance measure – is it FIT for purpose?

    by Khalid Bashir, Iosif Beintaris, Linda Sharp, Julia Newton, Katherine Elliott, Jon Rees, Peter Rogers, Matt Rutter

    Introduction Gastrointestinal symptoms correlate poorly with cancer diagnosis. A faecal immunochemical test (FIT) result of ≥10 µg has high sensitivity and negative predictive value for colorectal cancer (CRC) detection. An FIT-based diagnostic pathway may lead to more effective resource utilisation. We aimed to use National Endoscopy Database (NED) data to create a new colonoscopy performance measure, cancer detection rate (CDR) to assess the appropriate identification of target populations for colonoscopy; then to use CDR to assess the impact of implementing an FIT-based referral pathway locally. Methods NED data were analysed to compare local diagnostic colonoscopic CDR in 2019 (prepathway revision) and 2021 (postpathway revision), benchmarked against overall national CDR for the same time frames. Results 1, 123, 624 NED diagnostic colonoscopies were analysed. Locally, there was a significant increase in CDR between 2019 and 2021, from 3.01% (2.45%–3.47%) to 4.32% (3.69%–4.95%), p=0.003. The CDR increase was due to both a 10% increase in the number of CRCs detected and a 25% reduction in the number of diagnostic colonoscopies performed. Nationally, there was a smaller, but significant, increase in CDR from 2.02% (1.99%–2.07%) to 2.33% (2.29%–2.37%), pConclusion Our study indicates that the introduction of a robustly vetted FIT-based algorithm to determine whether diagnostic colonoscopy is required, is effective in increasing the colonoscopic CDR. Moreover, CDR appears to be a meaningful performance metric that can be automatically calculated through NED, enabling monitoring of the quality of referral and vetting pathways.


  • P264 Barrett’s oesophagus service delivery at a district general hospital in the North East of England

    by Muhammad Hamid Iqbal, Lesley Anne Gibb, Jamie Catlow, Christopher Wells, Roisin Bevan, John Jacob, Iosif Beintaris

    Introduction Standards for management of Barrett’s Oesophagus (BO) in the UK are outlined in the relevant British Society of Gastroenterology (BSG) guidelines. Each organisation should have a dedicated Barrett’s Team (BT) to facilitate delivery of a high quality service, from a clinical but also an administrative perspective. Our audit was designed to assess the administrative performance of the Barrett’s service in our Trust. Methods The audit was undertaken in two 6-month cycles from September 2020 to September 2021. Data was collected by reviewing endoscopy reports, histology and clinic letters. Service provision was assessed against the following standards: 1. All endoscopists diagnosing BO should copy the BT in the endoscopy report 2. All patients should receive a histology results letter, copied to the BT 3. All patients with a new diagnosis of BO should be offered a one–off outpatient clinic review 4. All patients with a new diagnosis of BO should be made aware of the premalignant nature of their diagnosis; this should be documented in relevant correspondence with the patient Results were disseminated to responsible clinical teams after the 1st and 2nd cycles. Practice outliers were directly contacted by the Endoscopy Clinical Lead, as per standard governance process when audits identify trends. A refresher training session on Barrett’s clinical and local administrative management was delivered in between cycles. Results The 1st cycle of the audit captured data from September 2020 to March 2021 inclusive. 231 patients were identified and 219 were eventually included. The BT were copied in 140 (65%) of endoscopy reports. Although 191 (89%) of cases had a histology results letter, only 110 (68%) of these letters were copied to the BT. 60 (27%) patients received a new diagnosis of BO, 17 (28%) of which were either discharged due to lack of true BO on review, or went on to a dysplasia/cancer pathway following index gastroscopy. of the remaining 43 patients, 22 (55%) had a new outpatient clinic requested on endoscopy report. Of the 60 new BO patients, 34 (57%) eventually received some type of BO-related correspondence/clinic review but only in 18 (53%) of these cases a discussion around the premalignant nature of BO was formally documented. The 2nd cycle of the audit identified 201 patients from April 2021 to September 2021; 181 patients were eventually included. The BT were copied in 125 (70%) of endoscopy reports. 145 (81%) of the patients had a histology letter sent but the BT were copied in only 97 (64%) of these letters. 32 (18%) patients received a new diagnosis of BO, from which 5 did not warrant clinic review due to lack of true BO on review. of the remaining 27 new BO patients, 16 (60%) had an outpatient clinic requested on endoscopy report. Of the 32 new BO patients, 21 (66%) eventually received some type of BO-related correspondence/clinic review but only in 17 (81%) cases a discussion around the premalignant nature of BO was formally documented. Results are summarized in the following chart: Conclusions Administrative management of Barrett’s oesophagus on a Trust level is equally important to adequate clinical management of the condition. This audit highlights that even when a local BT exists, engagement of the wider team of clinicians is key in ensuring patients receive appropriate follow up and are aware of the implications of their Barrett’s diagnosis. Endoscopists and responsible consultants need to implement these simple measures to their practice, to ensure BO patients are brought to the BT’s attention. When the 2nd cycle was performed, despite dissemination of results of the 1st cycle, delivery of a refresher training session and direct feedback to practice outliers, it was obvious that we are far from the goal of 100% for all audit standards. These gaps highlight a risk of patients being lost to follow up and GPs/patients not chasing recommended surveillance plans due to lack of awareness of the premalignant nature of BO. Further work is needed within individual Trusts to address human factors affecting high quality delivery of a BO service. Automation of the process of BT involvement whenever BO is mentioned in an endoscopy/histology report would offer a solid safety net in management of these patients.

  • Open Access

    P9 Outcomes from the UK purastat® registry: multicentre observational study of purastat® use in gastrointestinal bleeding

    by Sophie Arndtz, Sharmila Subramaniam, Ejaz Hossain, Mohamed Abdelrahim, Yeng Ang, Iosif Beintaris, Massimiliano di Pietro, Marietta Iacucci, Brian Saunders, Noriko Suzuki, et al.

    Introduction PuraStat® is a novel haemostatic agent without the risk of thermal injury, perforation or loss of mucosal views associated with other treatments such as heat therapy, clips or haemostatic powders. Our aim was to evaluate the efficacy of PuraStat® in the prevention and treatment of gastro-intestinal bleeding. Methods This is a prospective analysis of PuraStat® use in the UK, with 6 tertiary referral centres open to recruitment. Data was collected on procedure & lesion details, haemostasis management and complications for endoscopies where PuraStat® was used. Results 226 procedures were included across 3 indications: 198 high risk resection, 6 upper gastro-intestinal bleeding (UGIB) and 22 radiation proctopathy. PuraStat® was used for immediate haemostasis in 100 bleeding episodes, of which 92 were as primary agent and 8 as secondary agent (after failure of alternative initial therapy) and for prevention of delayed bleeding in 177 cases (see Table 1). PuraStat® was additionally used in 22 radiation proctopathy cases, as sole therapy in 14 and secondary therapy in 8, with improvement in patient reported symptom score and haemoglobin. The average volume of PuraStat® used across all indications was 0.43 mls for haemostasis and 2.33 mls for prevention of delayed bleeding. No PuraStat® related complications were reported. Haemostatic efficacy of PuraStat® Conclusions Our data shows PuraStat® is safe and effective for a range of indications, with most use within high risk resections. It shows high efficacy in both immediate haemostasis and prevention of delayed bleeding. We believe PuraStat® is a promising new agent in the prevention and management of gastro-intestinal bleeding.


  • Open Access

    O3 Water-assisted sigmoidoscopy in NHS bowel scope screening: the wash multicentre randomised controlled trial

    by M Rutter, Z Hoare, R Evans, C Von Wagner, T Larkin, L Spencer, E Holmes, J Deane, S Esmaily, B Saunders, et al.

    Introduction Bowel cancer is the UK’s 2nd most common cause of cancer death. To reduce this risk, the NHS Bowel Cancer Screening Programme invites 55-year olds for sigmoidoscopy (Bowel Scope Screening-BSS). A national patient survey showed much higher procedural pain than anticipated, potentially impacting on compliance and screening effectiveness. Studies indicate that a new technique using water-assisted scope insertion (WAS) may minimise bowel distension, hence reduce pain and also increase polyp detection. We aimed to assess the effect of WAS on procedural pain and adenomatous polyp detection, compared to CO2 assisted scope insertion. We aimed to perform a cost-effectiveness analysis of WAS, a discrete choice experiment (DCE) to ascertain patient preferences, and to survey trial endoscopists’ technique preference after the trial. Methods We performed an RCT of 1123 people undergoing BSS, randomised 1:1 to WAS (for which the endoscopists received training) or CO2. The primary outcome was patient-reported moderate/severe pain. The key secondary outcome was adenoma detection rate (ADR). Results We found no difference in patient-reported moderate/severe pain between WAS and CO2 (p=0.47;logistic regression; predictive marginal estimates 14% in WAS and 15% in CO2). Moderate/severe pain was significantly lower in both arms than in the previous national survey (pConclusions In the context of enema-prepared unsedated screening sigmoidoscopies performed by screening-accredited endoscopists, no difference in patient-reported pain was seen when using either a CO2 or WAS intubation technique. There is no need for screening sigmoidoscopists to switch to a WAS technique. Caution should be given to monitoring ADR if WAS is used in enema-prepared sigmoidoscopies. Research funded by NIHR RfPB. ISRCTN: 81466870


  • Top Cited Papers
    Open Access

    World Endoscopy Organization Consensus Statements on Post-Colonoscopy and Post-Imaging Colorectal Cancer

    by Matthew D. Rutter, Iosif Beintaris, Roland Valori, Han Mo Chiu, Douglas A. Corley, Miriam Cuatrecasas, Evelien Dekker, Anna Forsberg, Jola Gore-Booth, Ulrike Haug, et al.